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Abstract
Since HLA-restricted cytotoxic T-cell responses select specific polymorphisms in HIV-1
sequences and HLA diversity is relatively static in human populations, we investigated the use of
peptide epitopes based on sites of HLA-associated adaptation in HIV-1 sequences to stimulate and
detect T-cell responses ex-vivo. These “HLA-optimised” peptides captured more HIV-1 Nef-
specific responses compared with overlapping peptides of a single consensus sequence, in
interferon-γ enzyme linked immunospot assays. Sites of immune selection can reveal more
immunogenic epitopes in HLA-diverse populations and offer insights into the nature of HLA-
epitope targeting, which could be applied in vaccine design.
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1.0 Introduction
One of the challenges in HIV-1 vaccine design is the immense variability of the virus. The
variability over full length proteomes is a reflection of multiple forces, including neutral
evolution through multiple hosts, genetic bottlenecks at new transmissions and escape
mutations selected by immunological pressures within single hosts over time [1]. Among the
latter, HIV mutates within or near human leukocyte antigen (HLA)-restricted epitopes to
escape cytotoxic CD8 T-cell responses, either to disrupt T-cell receptor (TCR) recognition,
HLA-epitope binding or epitope processing [2,3]. Some mutations appear to create new
variant “neo-epitopes” which are also subject to immune responses [4]. It is therefore the
variation within or near HLA-restricted epitopes that is most functionally relevant to CD8 T-
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tcell reactivity. As HLA distributions remain relatively stable in the face of rapid HIV-1
evolution, HLA alleles and their allele-specific selection effects on the virus make viral
diversity, to some extent, predictable [1,5-9].
These points are equally applicable to the choice of stimulating antigens in assays of HIV-1-
specific CD8 T-cell responses, which continues to be of major interest for a wide range of
studies spanning HIV immunobiology and T-cell based HIV vaccine design. The most
commonly used capture assays of responses ex-vivo or of clonal T-cell populations rely on
short or long term stimulation of circulating T-cells with peptides that contain or correspond
to HLA-restricted T-cell epitopes in HIV-1. Peptides derived from HIV-1 reference
sequences based on laboratory isolates or population consensus sequences have contributed
a great deal to the accumulated knowledge of viral T-cell epitopes and responses to date;
however, responses against variant or subdominant epitopes may be missed using these
approaches [2,10-11]. A comparison of consensus and autologous sequence peptides showed
that 29% of responses were detected by autologous peptides only and that these responses
were directed towards epitopes in the variable regions of the virus [2]. Though highly
stringent, the cost of generating autologous peptide sets is prohibitive for large scale
screening studies. More recently, peptide design strategies that explicitly account for HIV
sequence diversity such as potential T-cell epitopes (PTEs), toggled peptides and peptides
derived from consensus, ancestral and centre-of-tree viral sequences have been developed
[10-13]. PTE peptides are derived from 110 full-length genome subtype B sequences and a
stepwise algorithm which generate ninety 15-mer peptides that cover 70% of population
sequence diversity [10,12]. As HIV sequence variation can be reduced to a few co-dominant
alternatives when epitope-length windows are considered, toggled peptides have epitope
variation embedded by including alternative amino acids during peptide synthesis. In
comparative studies using interferon (IFN)-γ enzyme linked immunospot (ELISpot) assays,
HIV-specific CD8 T-cell responses of higher breadth were detected with PTEs and toggled
peptides than matched consensus peptides [10,11], and in the case of toggled peptides, this
was explained by greater sequence similarity with the autologous virus [11]. Although
comparable IFN-γ responses were detected with peptides derived from consensus, centre-of-
tree and ancestor sequences, the range of responses detected was significantly broader when
a combination of all three sets was used which was attributed to an increased coverage of
viral diversity [13]. As a key principle, these studies demonstrate the functional importance
of HIV sequence variation to HLA-peptide-TCR interactions mediating T-cell reactivity in
immunoassays, and conceivably also important in responses to vaccines.
Here we have sought to examine whether the efficiency of diversity coverage in
immunoassays (and by implication in vaccine immunogens) could be improved by an
alternative approach based on optimising for HLA-restricted recognition at the population
level. These “polyallelic” peptides were conceived as a HIV-1 subtype B peptide reagent set
containing all well known optimal HLA-restricted CD8 T-cell epitopes as well as predicted
optimal epitopes spanning sites of evident HLA class I allele-specific polymorphism in
subtype B HIV-1, optimised for the HLA distribution of the tested population. By focussing
on “immunologically relevant” variation, we hypothesised that a broader range of responses
against optimal epitopes could be elicited with fewer assays. We compared the use of
polyallelic peptides to standard overlapping subtype B consensus peptides in detection of
HIV Nef-specific responses in the IFN-γ ELISpot assay. We carried out testing of both
peptide sets in parallel with the same patient samples under equivalent assay conditions. Nef
was chosen for the combination of high CD8 T-cell epitope density and high sequence
variability, allowing for the best chance of detecting a difference between the two peptide
sets in detection of variant-specific responses.
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t2.0 Materials and methods
2.1 Patient cohort
We studied 28 individuals with chronic HIV infection enrolled in the observational West
Australian (WA) HIV Cohort Study which operates under institutional review board
approval [14]. Selection of study subjects was necessarily restricted to those with stored
PBMCs in sufficient numbers for simultaneous ELISpot screening with both peptide sets.
Written informed consent was obtained from all patients. Medium to high resolution HLA
genotyping for all class I loci, plasma HIV RNA concentrations (viral load) and the
percentages of CD4 and CD8 T-cells most contemporaneous with ELISpot testing were
available for all individuals.
2.2 HLA-HIV polymorphism associations and putative epitopes
We used a reference set of phylogeny-adjusted associations between HLA alleles and
sequence polymorphisms across all HIV proteins computed in an independent subtype B
infected cohort, in which there was good statistical power over a diverse array of HLA
genotypes [15]. The specific amino acids representing the non-adapted/reversion/wild-type
or adapted/escaped residue at each site of HLA association were computed by the analysis.
After all viral amino acid-HLA associations were characterized, the consensus sequence of
the population surrounding sites of HLA-driven polymorphism was scanned with the ‘Epi-
pred’ epitope prediction program [16], http://atom.research.microsoft.com/bio/epipred.aspx].
In some cases, the epitope that was predicted to be a variant epitope induced by immune
pressure but still possibly immunogenic based on its predicted HLA-peptide binding
(“adapted epitopes”) was included. The prediction algorithm was trained on specified
characteristics of known CD8 T-cell epitopes; including epitope length, HLA-restriction and
the physicochemical properties of amino acids within and flanking epitopes [16]. Polyallelic
peptides therefore included predicted and known epitopes [17], regardless of whether the
epitope could be a target of selection in-vivo (non-adapted epitopes) or a variant capable of
inducing a de-novo immune response (adapted epitopes). All epitopes assigned with a
prediction probability score >0.4 were included in the polyallelic peptide set.
2.3 Formulation of polyallelic and overlapping peptide sets
The panel of polyallelic peptides comprising of sixty-two 8- to 11-mer peptides covering
HIV-1 clade B Nef were synthesized (Invitrogen, Victoria, Australia), solubilised and tested
as individual peptides. The responses to the polyallelic peptides were compared with those
elicited by forty-nine overlapping 15-mer peptides spanning a subtype B consensus Nef
sequence (AIDS Research and Reference Reagent Program, NIH, Maryland, United States
of America). These peptides overlapped by 11 amino acids and were set up in a matrix of 14
pools. Twenty-four peptides from the polyallelic peptide panel were embedded within the
overlapping peptides and the overlap between the two peptide sets is shown in Figure 1.
Lyophilized optimal and overlapping peptides were reconstituted in DMSO (VWR
International Ltd, Leicestershire, England) at 10 mg/mL stored at −20°C until used. The
final concentration of individual peptides whether tested singly or within pools was 2 μg/mL
and all peptides were tested in duplicate. Though the majority of patients screened by
ELISpot assays had HLA genotyping results available, testing of peptides were not limited
to those known to be restricted by the HLA genotype of each individual. The polyallelic
panel was tested in a standard fashion in all individuals in keeping with a screening strategy
and so that the correlation between responses and HLA genotype could be analysed post-
hoc.
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t2.4 IFN-γ ELISpot assay
Peripheral blood mononuclear cells (PBMCs) were separated using Accuspin tubes (Sigma,
Missouri, United States of America), stored and subsequently thawed when required. Cell
numbers and viability were assessed on the Vi-Cell XR (Beckman Coulter, Sydney,
Australia) and volume of media adjusted to give a concentration of 106 PBMCs/mL. IFN-γ
ELISpot assays were performed using the Biomek FX (Beckman Coulter) [18]. Anti-CD3
antibodies and pools of CMV-, EBV- and influenza (CEF)-derived peptides (Mabtech,
Victoria, Australia) were set up in duplicate or triplicate (final concentration=2 μg/mL) as
positive controls while triplicate negative controls consisted of PBMCs cultured in media
alone.
IFN-γ producing spots were enumerated using an AID ELISPOT reader (Autoimmun-
Diagnostika, Strassberg, Germany). The number of IFN-γ producing T-cells was determined
after subtraction of the background and expressed as SFUs/106 PBMCs [19].
2.5 Statistical methods
T-cell responses to both peptide sets were counted as positive if the number of spots were at
least twice as high as the background and had ≥50 SFUs/106 PBMCs. In addition to
fulfilling the above criteria, a peptide in the overlapping panel was included in the analysis
only if it elicited a response in two pools, with the magnitude of the response taken to be the
median of the two contributing pools. Peptide response rates were estimated as the
proportions of the peptides eliciting an IFN-γ response over a defined responder group. To
accommodate the correlation induced by multiple measures per patient, generalized
estimating equations were utilized for analysing the rates of response, and generalized linear
mixed effects models of log-transformed SFUs for assessing the magnitude of responses.
3.0 Results
The majority of patient in the cohort were male (89%) and all but four individuals were on
antiretroviral therapy. The median viral load was <50 HIV RNA copies/mL and median
percentage of CD4 and CD8 T-cells were 27% and 46% respectively. The HLA allele
frequency distribution was consistent with known ethnicity (predominantly white, European
ancestry; data not shown).
3.1 IFN- γ responses to polyallelic peptides
PBMCs from 61% of patients produced IFN-γ in response to stimulation by at least one
polyallelic peptide, with 80% of the peptides in the panel eliciting responses. The responder
and non-responder patients groups were balanced for the number per person of tested
epitopes that were HLA-matched (mean [SD]: 16.1 [4.8] vs 15.1 [6.8], p=0.7). There were
no significant differences between responders and non-responders in terms of percentage
CD4 T-cells (mean [SD]: 26% [9%] vs 29% [13%], p=0.5), CD8 T-cells (48% [11%] vs
48% [14%], p=0.9), or the proportions with undetectable viral load (65% vs 91%, p=0.2,
Fisher’s exact test). Only one of the eleven non-responders was not on therapy.
Amongst the 17 responders, the average response rate per peptide was 9.96%. Ninety-four
percent of responders directed at least one response to a peptide in the region between amino
acid residues 105 to 146 (HXB2 numbering). There was no observed correlation between
the breadth of responses and viral suppression, percentage of CD4 and CD8 T-cells,
treatment status or age.
As shown in Figure 2A, the median magnitude of the IFN-γ response to polyallelic peptides
was 120 SFUs/106 PBMCs (range=50-3500 SFUs/106 PBMCs). Ten of the 17 responders
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thad a maximum response above 200 SFUs/106 PBMCs. The magnitude of IFN-γ responses
was not associated with epitope adaptation, carriage of the HLA allele restricted to the
epitope, viral suppression, percentage of CD4 or CD8 T-cells, treatment status or age,
however, responses were marginally higher when directed against epitopes located in the
central Nef region (p=0.05).
3.2 IFN- γ responses to novel and variant (HLA-adapted) polyallelic peptides
Forty-one percent of responses were in patients carrying a matching HLA-allele restriction
of the stimulating epitope as previously published or predicted by the ‘Epi-pred’
programme. A further 18% of responses were in individuals with an HLA allele from the
same supertype group [20]and 26% were observed in individuals carrying an HLA allele
matching the restriction of an epitope overlapping the stimulating peptide (mean overlap of
7 amino acid residues) in the Nef protein.
Among the responses directed against central Nef epitopes, there was a predominance of
adapted epitopes that elicited an IFN-γ response. Seven of the 13 adapted epitopes elicited
responses in more than 20% of responders (FPLTFGWCF 35%; PLTFGWCYKL and
YPLTFGWCY 29%; KEKGGLEGI, KRQEILDLWVY, TRYPLTFGW and
TPGPGVRYPL 24%) compared with 2 of 9 of the non-adapted epitopes (RYPLTFGWCF
29%; TQGYFPDWQNY 24%). Carriage of the restricting HLA allele increased the
likelihood of response to adapted epitopes (mean response rate per adapted epitope amongst
HLA-matched carriers 12% vs 5% in non-carriers, p<0.0001), but IFN-γ response rates to
non-adapted epitopes did not differ significantly when carriage of the HLA-allele was
considered (carriers: 6%, non-carriers: 5%, p=0.7). Similar patterns of relative
responsiveness were observed when omitting the eleven non-responding patients from the
analyses (adapted epitopes: 18% vs 8%, p=0.0001; non-adapted epitopes: 10% vs 8%,
p=0.5) and also restricting further to include only those epitopes eliciting a response
(adapted epitopes: 21% vs 11%, p=0.002; non-adapted epitopes: 12% vs 10%, p=0.6).
3.3 Polyallelic versus overlapping consensus peptides
IFN-γ responses to pools of overlapping peptides were seen in 50% of tested individuals.
The magnitude of these responses (median [range] = 132 [50, 1595]) was very comparable
to that observed for the polyallelic peptides (p=0.8, Figure 2A). Forty-three percent of
individuals responded to both peptide sets and nine patients, all of whom were on therapy
and had undetectable viral loads, did not respond to either peptide set (Figure 3).
Of the 22 non-adapted epitopes from the polyallelic peptide set embedded within the
overlapping peptides, nine elicited responses in both peptide panels. There was no
significant difference in their estimated response rates (p=0.5, Figure 2B) nor the magnitude
of the responses (p=0.2). Notably, there was a very low response rate amongst those
overlapping peptides having no embedded peptides from the polyallelic set (p=0.0002,
Figure 2B).
3.4 Discussion
Polyallelic peptides have been designed to combat the problem of viral diversity by focusing
on that component of viral diversity that has functional relevance for CD8 T-cell responses.
Existing peptide approaches generally aim to incorporate all apparent viral variation,
including the variation reflecting phylogeny, random neutral changes, and non-T-cell
associated selection. These changes should not impact detection of CD8 T-cell responses at
the population level systematically, unless they occur predictably or stereotypically and have
functional effects on peptide presentation or HLA-peptide-TCR binding. In this study we
show that Nef peptides which are explicitly based on optimal immunogenic epitopes and
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ttheir variants and optimised as a group for the HLA distribution of the population are
associated with detection of more IFN-γ responses overall. The predominance of responses
to central Nef is consistent with previous observations on the intense clustering of CD8
epitopes [21-23] and the reason for broader reactivity to polyallelic peptides appears
attributable in part, to the inclusion of putative novel epitopes which elicited detectable IFN-
γ responses in the ELISpot assay (Figure 2B). These were predicted using sites of HLA
allele-specific polymorphism in HIV-1 sequence detected by large scale population-based
analyses, suggesting that these sites do mark targets of immune selection in-vivo and can be
used to map novel epitopes in HIV. This approach could therefore be extended to other HIV
proteins such as Gag and Pol as common vaccine proteins and also subject to HLA-driven
selection in-vivo.
Our testing suggests that a significant proportion of epitope variants contain HLA-driven
amino acid changes that do not affect HLA-peptide binding significantly. Presumably many
of these are TCR escape variants which are able to stimulate IFN-γ responses from memory
T-cells when in excess concentrations in a screening ELISpot assay; however more detailed
testing of relative functional avidity or off-rate assays may find differences compared with
the non-adapted epitopes. Notably some of these HLA-adapted epitopes (KY11 and TL10)
are also published and immunodominant epitopes [17], raising the possibility that they are
immunogenic by widely used immunoassays, but may alter TCR recognition for viral
advantage in-vivo.
Though polyallelic peptides were shorter (8 to 11-mer) optimal length peptides and tested
individually, we did not find evidence that this led to a greater magnitude of responses than
observed in the pools of longer (15-mer) overlapping peptides, or when compared to the
estimated individual overlapping peptide responses in cases where the same sequence was
present in both peptide sets. It is possible that responses to peptides present in the
overlapping peptides were potentially detectable in some individuals but were inhibited
completely because of competition between pooled peptides [24]. There was a significant
proportion of responses to the polyallelic peptides that could not be explained by the HLA
genotype or supertype of the tested PBMCs which may reflect ‘promiscuous’ HLA-peptide
binding as demonstrated in studies using overlapping peptides [21]. However the fact that
carriage of HLA alleles matching the known or predicted restriction of the polyallelic
peptides was associated with a greater response rate per peptide supports the proposition that
polyallelic peptides can be customised for the HLA of regional populations. Though HIV
diversifies rapidly at the population level, HLA distributions are relatively fixed and well
documented for many global populations so the known epitopes, novel epitopes, epitope
variants and supertype-cross binders most likely to stimulate the predominant CD8 T cell
responses are predictable [8]. A ranking of peptides based on HLA provides some rational
basis for prioritising peptides for testing when assays are limited by costs or PBMC
numbers. Furthermore, the polyallelic peptides have the advantage of identifying specific
epitope-specific CD8 T-cell responses at first testing, without the need for repeat
confirmatory tests and tests with truncated peptides to identify the true immunoreactive
epitope.
Among the current limitations of the strategy, CD4 T-cell responses are not likely to be
detected, and the success of detecting CD8 T-cell responses is heavily dependent on the
accuracy of the ‘Epi-pred’ program. PTEs and toggled peptides have been shown to improve
detection of CD8 T-cell responses compared to consensus strain peptides, and are currently
being used in variety of immunological studies. Direct head to head comparisons between
these and polyallelic strategies will be limited by the need for large numbers of PBMC for
parallel testing. There are immediate opportunities however to use the information on HLA-
specific polymorphisms, putative epitopes and HLA distribution to customise testing of
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tpeptides within any currently available set of peptides- PTEs, toggle peptides or overlapping
peptides- for HLA-diverse populations or within individuals with known HLA genotype.
Though the principles of design based on exploiting epitope clustering and population HLA
distribution can be applied to HIV vaccine design, we do not argue that all the epitope-
specific responses detected here should be necessarily induced by an effective preventative
HIV vaccine, particularly when many epitope variants are created as a result of HLA
associated polymorphism. If these represent the result of viral adaptation, then they may
have a negative effect if induced by a vaccine. Nevertheless, detection and characterisation
of all responses in natural HIV infection-whether effective or ineffective or virus- enhancing
in some way, is still needed to fully understand the HIV-specific T-cell response. In
particular, detection of responses is the first step to more detailed functional studies that
could determine the qualitative properties that distinguish effective T cell responses from all
others, and how best to harness these in a HIV vaccine.
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tFigure 1. Location of polyallelic peptides in relation to overlapping peptide set for the Nef region
of HIV-1
Overlapping peptides derived from a standard consensus clade B sequence, were 15-mer in
length and overlapped by 11 amino acid residues. Analyses of HLA-HIV associations were
used to construct a ‘cohort specific’ consensus sequence from which the polyallelic peptides
were generated. Published CD8 T-cell epitopes were also included in the panel of polyallelic
peptides. IFN-γ production was quantified in response to forty-nine overlapping peptides
and sixty-two polyallelic peptides. HLA-associations for each epitope in the polyallelic
peptide set are shown below the peptide. Differences between the overlapping and
polyallelic peptide sequences are highlighted in bold.
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tFigure 2. Magnitude of responses (A) and response rates (B) to the set of overlapping peptides
covering all of Nef and the set of polyallelic peptides identified as HLA-restricted epitopes within
Nef
There were no significant differences in the magnitude of responses (A) detected by the
panel of tested polyallelic peptides (△, median=120 SFUs/106 PBMCs) compared to the
overlapping peptides (▽, median=132 SFUs/106 PBMCs). Each of the two peptide sets were
split to further focus on common peptide sequences: embedded polyallelic peptides were
those sequences contained within an overlapping peptide; encompassing overlapping
peptides were those which contained at least one embedded polyallelic peptide within the
longer sequence. Similar response rates (p=0.5) were obtained for peptide sequences
common to sets (B). However, a significantly higher number of overlapping peptides
elicited a response when the peptide contained an embedded polyallelic epitope than if no
polyallelic peptide was present in the overlapping peptide sequence (p=0.0002).
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tFigure 3. Individual responses to polyallelic and overlapping peptide sets
Responses to polyallelic ( ) and overlapping ( ) peptides are shown for all 28 patients
tested in IFN-γ ELISpot assays. Of the 28 patients, 17 had responses to the polyallelic
peptide set while 12 potential epitopes were identified using overlapping peptides and 12
individuals had IFN-γ responses to both peptide sets.
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